Tags

Type your tag names separated by a space and hit enter

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Lancet Neurol 2009; 8(7):619-27LN

Abstract

BACKGROUND

Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in patients with subjective cognitive impairment (SCI) and non-amnestic mild cognitive impairment (naMCI) is unknown. AD is characterised by decreased CSF concentrations of Abeta(42) and increased concentrations of tau. We investigated the prevalence of a CSF AD profile in patients with SCI, naMCI, or aMCI and the association of this profile with cognitive outcome in each group.

METHODS

Patients with SCI, naMCI, aMCI, and neurologically healthy controls were recruited from 20 memory clinics across Europe, between January, 2003, and June, 2005, into this prospective cohort study. A CSF AD profile was defined as an abnormal ratio of Abeta(42):tau. Patients were assessed annually up to 3 years. Outcome measures were changes in memory, overall cognition, mini-mental state examination (MMSE) score, daily function, and progression to AD-type dementia.

FINDINGS

The CSF AD profile was more common in patients with SCI (31 of 60 [52%]), naMCI (25 of 37 [68%]), and aMCI (56 of 71 [79%]) than in healthy controls (28 of 89 [31%]). The profile was associated with cognitive decline in patients with naMCI (memory, MMSE, and daily function) and in patients with aMCI (MMSE and daily function). In patients with aMCI, a CSF AD profile was predictive of AD-type dementia (OR 26.8, 95% CI 1.6-456.4).

INTERPRETATION

AD is a common cause of SCI, naMCI, and aMCI and is associated with cognitive decline in patients with naMCI or aMCI. Patients with SCI might be in the early stages of AD, and cognitive decline might become apparent only after longer follow-up.

FUNDING

European Commission; Ana Aslan International Foundation.

Authors+Show Affiliations

Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, 6200 MD Maastricht, Netherlands. pj.visser@np.unimaas.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19523877

Citation

Visser, Pieter Jelle, et al. "Prevalence and Prognostic Value of CSF Markers of Alzheimer's Disease Pathology in Patients With Subjective Cognitive Impairment or Mild Cognitive Impairment in the DESCRIPA Study: a Prospective Cohort Study." The Lancet. Neurology, vol. 8, no. 7, 2009, pp. 619-27.
Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619-27.
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L. O., Freund-Levi, Y., ... Blennow, K. (2009). Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. The Lancet. Neurology, 8(7), pp. 619-27. doi:10.1016/S1474-4422(09)70139-5.
Visser PJ, et al. Prevalence and Prognostic Value of CSF Markers of Alzheimer's Disease Pathology in Patients With Subjective Cognitive Impairment or Mild Cognitive Impairment in the DESCRIPA Study: a Prospective Cohort Study. Lancet Neurol. 2009;8(7):619-27. PubMed PMID: 19523877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. AU - Visser,Pieter Jelle, AU - Verhey,Frans, AU - Knol,Dirk L, AU - Scheltens,Philip, AU - Wahlund,Lars-Olof, AU - Freund-Levi,Yvonne, AU - Tsolaki,Magda, AU - Minthon,Lennart, AU - Wallin,Asa K, AU - Hampel,Harald, AU - Bürger,Katharina, AU - Pirttila,Tuula, AU - Soininen,Hilkka, AU - Rikkert,Marcel Olde, AU - Verbeek,Marcel M, AU - Spiru,Luiza, AU - Blennow,Kaj, Y1 - 2009/06/10/ PY - 2009/6/16/entrez PY - 2009/6/16/pubmed PY - 2009/8/15/medline SP - 619 EP - 27 JF - The Lancet. Neurology JO - Lancet Neurol VL - 8 IS - 7 N2 - BACKGROUND: Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in patients with subjective cognitive impairment (SCI) and non-amnestic mild cognitive impairment (naMCI) is unknown. AD is characterised by decreased CSF concentrations of Abeta(42) and increased concentrations of tau. We investigated the prevalence of a CSF AD profile in patients with SCI, naMCI, or aMCI and the association of this profile with cognitive outcome in each group. METHODS: Patients with SCI, naMCI, aMCI, and neurologically healthy controls were recruited from 20 memory clinics across Europe, between January, 2003, and June, 2005, into this prospective cohort study. A CSF AD profile was defined as an abnormal ratio of Abeta(42):tau. Patients were assessed annually up to 3 years. Outcome measures were changes in memory, overall cognition, mini-mental state examination (MMSE) score, daily function, and progression to AD-type dementia. FINDINGS: The CSF AD profile was more common in patients with SCI (31 of 60 [52%]), naMCI (25 of 37 [68%]), and aMCI (56 of 71 [79%]) than in healthy controls (28 of 89 [31%]). The profile was associated with cognitive decline in patients with naMCI (memory, MMSE, and daily function) and in patients with aMCI (MMSE and daily function). In patients with aMCI, a CSF AD profile was predictive of AD-type dementia (OR 26.8, 95% CI 1.6-456.4). INTERPRETATION: AD is a common cause of SCI, naMCI, and aMCI and is associated with cognitive decline in patients with naMCI or aMCI. Patients with SCI might be in the early stages of AD, and cognitive decline might become apparent only after longer follow-up. FUNDING: European Commission; Ana Aslan International Foundation. SN - 1474-4422 UR - https://www.unboundmedicine.com/medline/citation/19523877/Prevalence_and_prognostic_value_of_CSF_markers_of_Alzheimer's_disease_pathology_in_patients_with_subjective_cognitive_impairment_or_mild_cognitive_impairment_in_the_DESCRIPA_study:_a_prospective_cohort_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1474-4422(09)70139-5 DB - PRIME DP - Unbound Medicine ER -